Related Tags >> DX-88 Phase III FDA GlaxoSmithKline

Dyax News

Most Popular Dyax Story

Sanofi to pay $500M for Dyax antibody program

February 12, 2008 — 6:59am ET

Sanofi-Aventis has committed up to $500 million for the worldwide rights to Dyax's DX-2240 human monoclonal Read more...

Dyax Press Releases

Latest Headlines

Drug prices jump 9.1% in biggest rise of the decade; Genmab gains $16M milestone;
April 20, 2010
Cubist shelves ecallantide program
April 1, 2010
Dyax investors bid up shares on FDA's Kalbitor approval
December 2, 2009
Sanofi deal spree creates closer ties with Dyax
October 13, 2009
Dyax chops 60 jobs after FDA delay
March 31, 2009
Dyax shares sink as FDA rejects drug
March 27, 2009
Biogen, Dyax ink $84M IP deal
February 5, 2009
FDA panel narrowly votes in favor of Dyax drug
February 5, 2009
FDA staffers question Dyax studies
February 3, 2009
Dyax shares soar on late-stage DX-88 data
August 18, 2008
ALSO NOTED: Dyax to close R&D facility;Nastech sells shares; and much more...
April 28, 2008
Dyax forges $231M development deal for DX-88
April 24, 2008
Sanofi to pay $500M for Dyax antibody program
February 12, 2008
ALSO NOTED: Cross Country expands research offering; Dyax prices shares; Sciele takes stake in Addrenex; and much more...
July 13, 2007
Analysts see a continuing surge of licensing deals
June 26, 2007
ALSO NOTED: Intradigm completes $16M Series A financing; Prana to raise $6M to fund trial; and much more...
November 20, 2006
Jerini drug for HAE produces mixed results
September 21, 2006
DEALS: GSK, ChemoCentryx ink $1.5B pact
August 30, 2006
Dyax pockets $30M in revenue deal
August 24, 2006
Dyax sent back for more data on DX-88
May 15, 2006

Paid Research Reports

More Research Reports >>